News | May 03, 2025
Sanofi Consumer Healthcare India Q1 PAT up 12.9%
The Q1 2025 also witnessed a successful launch of Allegra D
The Q1 2025 also witnessed a successful launch of Allegra D
The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.
The Subsidiary has received one inspectional observation in Form 483
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
Priced at just Rs. 499 for 1-year supply, this initiative is aligned with the vision of Health for All
Vimta Labs has reported total income of Rs. 96.08 crores during the period ended March 31, 2025
The transaction structured as share swap, is valued at ~Rs. 849 crore, with no cash outflow
ekincare has raised a total funding of $22M since 2015 till date
Subscribe To Our Newsletter & Stay Updated
